arrow
返回
R

Robert H. Hyland

Gilead Sciences

54H指数
220论文数
2.0W被引数
收录论文 47
发表时间
Efficacy and safety of obeldesivir in low-risk, non-hospitalised patients with COVID-19 (OAKTREE): a phase 3, randomised, double-blind, placebo-controlled study奥贝德西韦在低风险、非住院COVID-19患者中的有效性与安全性(OAKTREE):一项III期、随机、双盲、安慰剂对照研究
err2025-07-14
err0
PREAI
errOnyema Ogbuagu; Jason D Goldman; Robert L Gottlieb; Upinder Singh; Masaharu Shinkai; Gerard Acloque; Dahlene N Fusco; Erika Gonzalez; Princy Kumar; Anne Luetkemeyer; Amos Lichtman; Afsaneh Mozaffarian; Yiannis Koullias; Robert H Hyland; Joe Llewellyn; Anu Osinusi; Frank Duff; Rita Humeniuk; Luzelena Caro; Santosh Davies
err分享
err收藏
Obeldesivir for Treatment of COVID-19 in Adults and Adolescents Without Risk Factors for Progression to Severe Disease: the OAKTREE Study奥贝拉米韦用于无进展至重症疾病风险因素成人和青少年COVID-19患者的治疗:OAKTREE研究
err2025-01-29
err0
PREAI
errOgbuagu, Onyema; Goldman, Jason D.; Gottlieb, Robert L.; Singh, Upinder; Shinkai, Masaharu; Acloque, Gerard; Fusco, Dahlene; Gonzalez, Erika; Kumar, Princy N.; Luetkemeyer, Annie; Lichtman, Amos; Mozaffarian, Afsaneh; Koullias, Yiannis; Hyland, Robert H.; Llewellyn, Joe; Osinusi, Anu; Duff, Frank; Humeniuk, Rita; Caro, Luzelena; Davies, Santosh; Hedskog, Charlotte; Chen, Shuguang; Etchevers, Kim; Nadig, Priyanka; Kohli, Anita
err分享
err收藏
Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients
err2022-01-27
err865
errOAAI
errGottlieb, R. L.; Vaca, C. E.; Paredes, R.; Mera, J.; Webb, B. J.; Perez, G.; Oguchi, G.; Ryan, P.; Nielsen, B. U.; Brown, M.; Hidalgo, A.; Sachdeva, Y.; Mittal, S.; Osiyemi, O.; Skarbinski, J.; Juneja, K.; Hyland, R. H.; Osinusi, A.; Chen, S.; Camus, G.; Abdelghany, M.; Davies, S.; Behenna-Renton, N.; Duff, F.; Marty, F. M.; Katz, M. J.; Ginde, A. A.; Brown, S. M.; Schiffer, J. T.; Hill, J. A.
err分享
err收藏
Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection
err2017-06-01
err445
errOAAI
errBourliere, M.; Gordon, S. C.; Flamm, S. L.; Cooper, C. L.; Ramji, A.; Tong, M.; Ravendhran, N.; Vierling, J. M.; Tran, T. T.; Pianko, S.; Bansal, M. B.; Ledinghen, V. de; Hyland, R. H.; Stamm, L. M.; Dvory-Sobol, H.; Svarovskaia, E.; Zhang, J.; Huang, K. C.; Subramanian, G. M.; Brainard, D. M.; McHutchison, J. G.; Verna, E. C.; Buggisch, P.; Landis, C. S.; Younes, Z. H.; Curry, M. P.; Strasser, S. I.; Schiff, E. R.; Reddy, K. R.; Manns, M. P.; Kowdley, K. V.; Zeuzem, S.
err分享
err收藏
NO IMPACT OF RASS ON THE HIGH EFFICACY OF SOF/VEL/VOX FOR 12 WEEKS IN DAA-EXPERIENCED PATIENTS: AN INTEGRATED RESISTANCE ANALYSIS OF THE POLARIS-1 AND POLARIS-4 STUDIES
err2017-04-01
err0
PREAI
errReddy, K. Rajender; Cooper, Curtis L.; Manns, Michael; Kowdley, Kris V.; Spellman, James; Llewellyn, Joseph; Dvory-Sobol, Hadas; Svarovskaia, Evguenia; Martin, Ross; Doehle, Brian P.; Camus, Gregory; Stamm, Luisa; Hyland, Robert H.; Brainard, Diana; Mo, Hongmei; Gordon, Stuart C.; Bourliere, Marc; Zeuzem, Stefan; Flamm, Steven L.; Sarrazin, Christoph
err分享
err收藏
NO IMPACT OF RASS ON THE HIGH EFFICACY OF SOF/VEL/VOX FOR 8 WEEKS IN DAA-NAIVE PATIENTS: AN INTEGRATED RESISTANCE ANALYSIS OF THE POLARIS-2 AND POLARIS-3 STUDIES
err2017-04-01
err0
PREAI
errLawitz, Eric; Wyles, David L.; Thompson, Alexander; Willems, Bernard; Gane, Edward; Rivera, Omar J.; Svarovskaia, Evguenia; Dvory-Sobol, Hadas; Martin, Ross; Camus, Gregory; Doehle, Brian P.; Stamm, Luisa; Hyland, Robert H.; Brainard, Diana; Mo, Hongmei; Asselah, Tarik; Jacobson, Ira M.; Foster, Graham R.; Roberts, Stuart
err分享
err收藏
SOF/VEL/VOX RESULTS IN HIGH SVR12 RATES WHEN ADMINISTERED FOR 12 WEEKS IN DAA-EXPERIENCED PATIENTS OR FOR 8 WEEKS IN DAA-NAIVE PATIENTS: AN INTEGRATED ANALYSIS OF THE POLARIS-1, POLARIS-2, POLARIS-3 AND POLARIS-4 STUDIES
err2017-04-01
err0
PREAI
errFlamm, Steven L.; Roberts, Stuart; Cooper, Curtis L.; Lawitz, Eric; Reddy, K. Rajender; Thompson, Alexander; Zeuzem, Stefan; Jacobson, Ira M.; Ruane, Peter J.; Mehta, Swarup S.; Hyland, Robert H.; Stamm, Luisa; Han, Lingling; Brainard, Diana; Brau, Norbert; Asselah, Tarik; Willems, Bernard; Bourliere, Marc; Foster, Graham R.; Gane, Edward; Manns, Michael; Gordon, Stuart C.; Kowdley, Kris V.
err分享
err收藏
THE SAFETY AND TOLERABILITY OF SOF/VEL/VOX FOR 8 OR 12 WEEKS IN >1,000 PATIENTS TREATED IN THE POLARIS-1, POLARIS-2, POLARIS-3, AND POLARIS-4 STUDIES: AN INTEGRATED ANALYSIS
err2017-04-01
err0
PREAI
errGordon, Stuart C.; Gane, Edward; Willems, Bernard; Roberts, Stuart A.; Flamm, Steven L.; Bourliere, Marc; Asselah, Tarik; Alric, Laurent; Letterio, Cathleen; Llewellyn, Joe; Hyland, Robert H.; Stamm, Luisa; Huang, K. C.; Brainard, Diana; Khalili, Mandana; Foster, Graham R.; Manns, Michael; Reddy, K. Rajender; Zeuzem, Stefan; Jacobson, Ira M.; Cooper, Curtis L.; Thompson, Alexander; Kowdley, Kris V.; Lawitz, Eric
err分享
err收藏
Ledipasvir-sofosbuvir and sofosbuvir plus ribavirin in patients with chronic hepatitis C and bleeding disorders
err2017-01-25
err25
PREAI
errWalsh, C. E.; Workowski, K.; Terrault, N. A.; Sax, P. E.; Cohen, A.; Bowlus, C. L.; Kim, A. Y.; Hyland, R. H.; Han, B.; Wang, J.; Stamm, L. M.; Brainard, D. M.; McHutchison, J. G.; von Drygalski, A.; Rhame, F.; Fried, M. W.; Kouides, P.; Balba, G.; Reddy, K. R.
err分享
err收藏
The safety and tolerability of SOF/VEL/VOX for 8 or 12 weeks in >1,000 patients treated in the POLARIS-1, POLARIS-2, POLARIS-3, and POLARIS-4 studies: an integrated analysis
err2017-01-01
err4
PREAI
errManns, M.; Gane, E. J.; Willems, B. E.; Roberts, S. K.; Flamm, S.; Bourliere, M.; Asselah, T.; Alric, L.; Hyland, R. H.; Stamm, L. M.; Huang, K. C.; Brainard, D. M.; Khalili, M.; Foster, G. R.; Gordon, S. C.; Reddy, K. R.; Zeuzem, S.; Jacobson, I. M.; Cooper, C. L.; Thompson, A. J.; Kowdley, K.; Lawitz, E.
err分享
err收藏
No impact of RASs on the high efficacy of SOF/VEL/VOX for 8 weeks in DAA-naive patients: an integrated resistance analysis of the POLARIS-2 and POLARIS-3 studies
err2017-01-01
err2
PREAI
errWyles, D.; Thompson, A.; Lawitz, E.; Willems, B.; Gane, E. J.; Svarovskaia, E.; Dvory-Sobol, H.; Martin, R.; Camus, G.; Doehle, B. P.; Stamm, L. M.; Hyland, R. H.; Brainard, D. M.; Mo, H. M.; Asselah, T.; Jacobson, I.; Foster, G. R.; Roberts, S.
err分享
err收藏
No impact of RASs on the high efficacy of SOF/VEL/VOX for 12 weeks in DAA-experienced patients: an integrated resistance analysis of the POLARIS-1 and POLARIS-4 studies
err2017-01-01
err5
PREAI
errSarrazin, C.; Cooper, C. L.; Manns, M. P.; Reddy, R. K.; Kowdley, K.; Dvory-Sobol, H.; Svarovskia, E.; Martin, R.; Doehle, B. P.; Camus, G.; Stamm, L. M.; Hyland, R. H.; Brainard, D. M.; Mo, H.; Gordon, S. C.; Bourliere, M.; Zeuzem, S.; Flamm, S. L.
err分享
err收藏
SOF/VEL/VOX results in high SVR12 rates when administered for 12 weeks in DAA-experienced patients or for 8 Weeks in DAA-naive patients: an integrated analysis of the POLARIS-1, POLARIS-2, POLARIS-3 and POLARIS-4 studies
err2017-01-01
err1
PREAI
errRoberts, S. K.; Cooper, C. L.; Lawitz, E.; Reddy, K. R.; Thompson, A. J.; Zeuzem, S.; Jacobson, I. M.; Ruane, P.; Hyland, R. H.; Stamm, L. M.; Han, L.; Brainard, D. M.; Brau, N.; Asselah, T.; Willems, B. E.; Flamm, S.; Bourliere, M.; Foster, G. R.; Gane, E. J.; Manns, M.; Gordon, S. C.; Kowdley, K.
err分享
err收藏
Prevalence of infection with multiple strains of hepatitis C virus (HCV) in patients enrolled in HCV clinical trials
err2017-01-01
err1
PREAI
errWelzel, T. M.; Ryan, M.; Hedskog, C.; Bhardwaj, N.; Hyland, R. H.; Martin, R.; Stamm, L. M.; Brainard, D. M.; Mo, H.; Svarovskaia, E.; Nahass, R. G.; Schiff, E. R.; Katlama, C.
err分享
err收藏
HIGH EFFICACY OF SOFOSBUVIR/VELPATASVIR/GS-9857 WITH OR WITHOUT RIBAVIRIN FOR 12 WEEKS IN DIRECT ACTING ANTIVIRAL-EXPERIENCED PATIENTS WITH GENOTYPE 1 HCV INFECTION
err2016-01-01
err3
PREAI
errLawitz, E.; Poordad, F.; Wells, J.; Hyland, R. H.; Yang, Y.; Dvory-Sobol, H.; Stamm, L. M.; Brainard, D. M.; McHutchison, J. G.; Landaverde, C.; Gutierrez, J.
err分享
err收藏
RESISTANCE ANALYSIS OF GENOTYPE 1 OR 3 HCV-INFECTED PATIENTS TREATED WITH SOFOSBUVIR/VELPATASVIR+GS-9857 FOR 6 OR 8 WEEKS
err2016-01-01
err1
PREAI
errGane, E.; Svarovskaia, E. S.; Dvory-Sobol, H.; Hyland, R. H.; Stamm, L. M.; Brainard, D. M.; Miller, M. D.; Mo, H.; Schwabe, C.; Stedman, C. A.
err分享
err收藏
LONG-TERM FOLLOW-UP OF PATIENTS WITH CHRONIC HCV INFECTION FOLLOWING TREATMENT WITH DIRECT ACTING ANTIVIRAL REGIMENS: MAINTENANCE OF SVR, PERSISTENCE OF RESISTANCE MUTATIONS AND CLINICAL OUTCOMES
err2016-01-01
err5
PREAI
errLawitz, E. J.; Ruane, P.; Stedman, C.; Foster, G.; Hyland, R. H.; Coogan, S.; Moody, S.; Dvory-Sobol, H.; Knox, S. J.; Brainard, D. M.; Abergel, A.; Agarwal, K.; Younes, Z.; Schwabe, C.
err分享
err收藏
Ledipasvir/Sofosbuvir With or Without Ribavirin for the Treatment of Patients With Genotype 2-6 Chronic HCV Infection: Summary Results From Four Phase II Studies
err2015-10-01
err1
PREAI
errGane, Edward; Stedman, Catherine A. M.; Asselah, Tarik; Kohli, Anita; Mir, Heshaam M.; Natha, Macky; Kersey, Kathryn; Hyland, Robert H.; McHutchison, John G.; Abergel, Armand
err分享
err收藏
err分享
err收藏
SAFETY AND EFFICACY OF SHORT-DURATION TREATMENT WITH GS-9857 COMBINED WITH SOFOSBUVIR/GS-5816 IN TREATMENT-NAIVE AND DAA-EXPERIENCED GENOTYPE 1 PATIENTS WITH AND WITHOUT CIRRHOSIS
err2015-04-01
err10
PREAI
errGane, E. J.; Hyland, R. H.; Ying, Y.; Svarovskaia, E.; Stamm, L. M.; Brainard, D. M.; Subramanian, G. M.; McHutchison, J. G.; Schwabe, C.
err分享
err收藏